FRI0230 Tocilizumab in the real clinical practice: a preliminary descriptive analysis from the italian observational trust study

Background Tocilizumab (TCZ) is a humanised monoclonal antibody that inhibits binding of interleukin-6 (IL-6) to its receptors1, preventing IL-6–mediated pro-inflammatory activity. TCZ in combination with methotrexate (MTX) is indicated in patients with moderate to severe Rheumatoid Arthritis (RA) with inadequate clinical response or intolerance to one or more DMARDs or TNF-α antagonists. Moreover, TCZ is indicated as monotherapy in patients intolerant to MTX or for whom MTX is considered inappropriate1. So far few data are available about the use and clinical impact of TCZ in the real clinical practice. Objectives Objectives: The primary objective of this multicenter, retrospective and prospective, observational study was to evaluate the percentage of RA patients who achieved low disease activity (DAS28 ≤3.2) and remission (DAS28